-
Signature
-
/s/ Tobin Schilke, as attorney-in-fact
-
Stock symbol
-
CRNX
-
Transactions as of
-
Jun 12, 2025
-
Transactions value $
-
-$2,850,799
-
Form type
-
4
-
Date filed
-
6/16/2025, 04:48 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Betz Stephen F. |
Chief Scientific Officer |
C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO |
/s/ Tobin Schilke, as attorney-in-fact |
2025-06-16 |
0001886575 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CRNX |
Common Stock |
Options Exercise |
$137K |
+71.5K |
+65.6% |
$1.91 |
181K |
Jun 12, 2025 |
Direct |
F1 |
| transaction |
CRNX |
Common Stock |
Options Exercise |
$154K |
+16.6K |
+9.22% |
$9.28 |
197K |
Jun 12, 2025 |
Direct |
|
| transaction |
CRNX |
Common Stock |
Sale |
-$3.14M |
-97.5K |
-49.43% |
$32.23 |
99.7K |
Jun 12, 2025 |
Direct |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CRNX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-71.5K |
-39.73% |
$0.00 |
109K |
Jun 12, 2025 |
Common Stock |
71.5K |
$1.91 |
Direct |
F4 |
| transaction |
CRNX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-16.6K |
-22.24% |
$0.00 |
58.2K |
Jun 12, 2025 |
Common Stock |
16.6K |
$9.28 |
Direct |
F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: